Pharmacological Treatment for Patients with Obesity and Heart Failure: Focus on Glucagon-Like Peptide-1 Receptor Agonists. European Journal of Heart Failure Expert Consensus Document

In HF with preserved ejection fraction (HFpEF), trials have shown meaningful reductions in body weight with improvements in health status and exercise capacity

Whether these effects translate into fewer heart failure (HF) events or lower CV mortality remains uncertain (two small trials, few events)

Data on efficacy and safety in HF with reduced ejection fraction are scarce; dedicated outcome trials yet to be launched